Follow The Filings

NKTR Nektar Therapeutics

Health Care, filed as NEKTAR THERAPEUTICS (COM NEW), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 4.2%
  • $20M
  • 1 add

In 2026 Q3 Nathan Fischel added to Nektar Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 4.2% (Nathan Fischel, DAFNA Capital Management). Not free-float ownership.

  1. Nathan Fischel Add 4.2%

Who owns NKTR

Sorted by value, long equity only, as of 2026 Q3.

History
Nathan Fischel, DAFNA Capital Management 4.2% Add +1.6% 323,380 $20M History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NKTR's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NKTR insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $2.1M sold by 2 insiders under 10b5-1 plans
  1. Jonathan Zalevsky Chief R&D Officer
    Planned sale
    $398K 5,681 shares at $70.00 37% of stake
    Traded Jun 30 Filed Jul 2
  2. Howard W. Robin CEO
    Planned sale
    $1.2M 20,000 shares at $60.75 27% of stake
    Traded Jun 16–17 Filed Jun 18
  3. Jonathan Zalevsky Chief R&D Officer
    Planned sale
    $336K 5,538 shares at $60.71 26% of stake
    Traded Jun 15 Filed Jun 17
  4. Jonathan Zalevsky Chief R&D Officer
    Planned sale
    $138K 3,867 shares at $35.67 15% of stake
    Traded Jan 20 Filed Jan 22

Also filed in the last 12 months, not counted as buying or selling: 11 sales to cover taxes and 7 stock grants.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
10-Q
8-K 7.01
8-K 2.02,9.01
SCHEDULE 13G —
8-K 7.01,9.01
SCHEDULE 13G/A —
8-K 8.01
8-K 7.01,9.01
SCHEDULE 13G/A —
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
SCHEDULE 13G —
8-K 5.07
SCHEDULE 13G/A —
10-Q
8-K 1.01,5.02,9.01
424B5
8-K 2.02,9.01
SCHEDULE 13G/A —
DEF 14A
DEFA14A
8-K 1.01,8.01,9.01

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $90.12M $98.43M $55.23M
Gross profit * $56.35M $67.74M $55.23M
Gross margin * 62.5% 68.8% 100.0%
Net income -$276.06M -$118.96M -$164.08M
Net margin * -306.3% -120.9% -297.1%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $330.7M $261.29M $266.27M
Total non-current assets * $67.33M $42.56M $14.14M
Total assets $398.03M $303.85M $280.41M
Total current liabilities $51.27M $61.4M $53.54M
Total non-current liabilities * $215.78M $181.71M $137.04M
Total equity $130.99M $60.74M $89.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$192.61M -$175.71M -$208.51M
Cash from investing $139.56M $142.57M -$1.2M
Cash from financing $0.03M $42.12M $180.57M
Net change in cash -$52.95M $8.98M -$29.14M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf